Yahoo Finance's Anjalee Khemlani joins the Live show to discuss Moody's outlook for pharmaceutical industry as well as reports that Pfizer is looking to provide additional COVID-19 vaccine doses.
Shares of AbbVie (NYSE: ABBV) are up by about 13% this year, which is a lot better than the benchmark S&P 500 index, which has lost 20% over the same period. With lots of high-margin revenue from top-selling drugs, there's a good chance that AbbVie stock will remain a safe haven even if the U.S. economy plunges into a deep recession. The top-selling drug for AbbVie is Humira.
Let's look at two stocks worth investing $5,000 in right now for investors who want to score market-beating returns in the long run: AbbVie (NYSE: ABBV) and Intuitive Surgical (NASDAQ: ISRG). Shares of AbbVie have easily outperformed the market this year, but the company remains reasonably valued. At these levels, AbbVie is an outstanding stock to buy considering the strength of its underlying business.